Ryzodeg Flexpen100 IU/ml

Ryzodeg Flexpen is indicated to improve glycemic control in adults and pediatric patients (1 year of age and older) with diabetes mellitus who require both basal (background) and prandial (mealtime) insulin coverage.

Ryzodeg Flexpen is not recommended in pediatric patients who require a total daily insulin dose of less than 5 units, because of imprecise dosing at very low volumes.

Insulin Degludec + Insulin Aspart Premixed is a premixed, fixed-ratio combination insulin analogue preparation, commonly formulated as a solution containing insulin degludec and insulin aspart in a fixed ratio (e.g., 70% insulin degludec / 30% insulin aspart per unit), supplied as a sterile solution for subcutaneous injection in prefilled pens or vials.

Exact strength, ratio, and pack size vary by manufacturer and locally marketed brand; always confirm the specific product label and unit strength (units/mL) dispensed.

Ryzodeg Flexpen combines two insulin analogues in a single formulation: insulin degludec, an ultra-long-acting basal insulin that forms soluble multi-hexamer depots under the skin for slow, steady release over more than 24 hours, and insulin aspart, a rapid-acting insulin analogue that provides a fast onset of action to control the rise in blood glucose that occurs after meals.

By combining both components in one injection, Ryzodeg Flexpen allows patients who require both basal and prandial insulin coverage to achieve glycemic control with fewer daily injections, while maintaining distinct, non-overlapping pharmacokinetic profiles for each component.

Ryzodeg Flexpen belongs to the therapeutic class of antidiabetic agents — premixed insulin analogue combinations, combining an ultra-long-acting basal insulin analogue with a rapid-acting insulin analogue.

Pharmacodynamics

Insulin Degludec + Insulin Aspart Premixed exhibits a dual, non-overlapping action profile. The insulin aspart component has a rapid onset (within 10–20 minutes) and short duration (3–5 hours), reducing post-prandial glucose excursions. The insulin degludec component self-associates into soluble multi-hexamers after subcutaneous injection, forming a depot from which monomers are slowly and continuously absorbed, producing a flat, stable, and prolonged glucose-lowering effect lasting beyond 24 hours with low day-to-day variability.

Pharmacokinetics

Insulin aspart reaches peak serum concentration approximately 60–90 minutes after injection. Insulin degludec reaches pharmacokinetic steady state after 2–3 daily doses and has an elimination half-life of approximately 25 hours, independent of dose and injection site.

• Ryzodeg Flexpen is for subcutaneous injection only — administer into the abdomen, thigh, or upper arm, rotating injection sites within the same region to reduce the risk of lipodystrophy.
• Do not administer intravenously or intramuscularly.
• Inject with a meal to align the rapid-acting (aspart) component with mealtime glucose rise; do not skip the meal after injecting.
• Do not mix or dilute with any other insulin product or solution in the same syringe or pen.
• Always check the dose counter/window on the pen before injecting; visually inspect the solution, which should appear clear and colorless.
• Never share a pen or syringe/needle between patients, even if the needle is changed, due to the risk of transmitting blood-borne infections.

Several drug classes clinically alter the glucose-lowering effect of Ryzodeg Flexpen or mask hypoglycemia symptoms:

• Agents that may increase hypoglycemia risk: other antidiabetic agents (sulfonylureas, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT-2 inhibitors), ACE inhibitors, angiotensin receptor blockers, salicylates, monoamine oxidase inhibitors, fibrates, fluoxetine, disopyramide, and pentoxifylline.
• Agents that may decrease glucose-lowering effect (raise blood glucose): corticosteroids, thiazide diuretics, danazol, thyroid hormones, sympathomimetics (e.g., albuterol, epinephrine), growth hormone, and certain protease inhibitors and atypical antipsychotics.
• Agents that may mask signs/symptoms of hypoglycemia: beta-blockers, clonidine, guanethidine, and reserpine — extra vigilance with glucose monitoring is needed.
• Thiazolidinediones (TZDs): co-administration with insulin, including Ryzodeg Flexpen, increases the risk of fluid retention and heart failure, particularly in patients with pre-existing cardiac risk factors.
• Alcohol: can potentiate or prolong hypoglycemic effect.

The most common and most serious adverse reaction associated with Ryzodeg Flexpen is hypoglycemia (see Precautions and Warnings for full discussion).

• Hypoglycemia (very common; can be serious and life-threatening)
• Weight gain
• Injection site reactions (redness, swelling, itching)
• Lipodystrophy (lipohypertrophy or lipoatrophy) with repeated injection at the same site
• Peripheral edema, especially when starting insulin therapy or intensifying control
• Nasopharyngitis, headache, upper respiratory tract infection
• Rare but serious: generalized allergic reactions, including anaphylaxis

Pregnancy: Insulin requirements typically change during pregnancy and the postpartum period. Ryzodeg Flexpen should be used during pregnancy only if clearly needed and if the potential benefit to the mother justifies the potential risk to the fetus; close glucose monitoring and dose adjustment by a physician are essential throughout pregnancy. Poorly controlled diabetes during pregnancy carries risks to both mother and fetus, so insulin therapy should not be discontinued without medical advice.

Lactation: Insulin is generally considered compatible with breastfeeding, as it is a naturally occurring hormone; however, insulin dose and diet may need adjustment while breastfeeding. Consult a physician before and during use while breastfeeding.

• Hypoglycemia: the most frequent and potentially life-threatening risk with Ryzodeg Flexpen; can cause seizures, loss of consciousness, or death if severe and untreated. Risk is increased with intensified glycemic control, skipped or delayed meals, unplanned exercise, alcohol intake, and concomitant use of other glucose-lowering agents. Symptoms may be blunted or absent in patients with long-standing diabetes, autonomic neuropathy, or those taking beta-blockers.
• Never change insulin products (brand, type, or manufacturer) without medical supervision — Ryzodeg Flexpen has a distinct pharmacokinetic profile from other basal-only or premixed insulin products, and switching without physician guidance and dose re-titration can cause severe hypo- or hyperglycemia.
• Hypokalemia: insulin therapy can shift potassium intracellularly; monitor in patients at risk (e.g., those on potassium-lowering medications).
• Fluid retention and heart failure: risk increases when insulin is co-administered with thiazolidinediones.
• Illness, surgery, changes in diet, travel, or altered activity levels may require dose adjustment; consult a physician before making changes.
• Use caution when driving or operating machinery, due to risk of hypoglycemia affecting concentration and reaction time.
• Rotate injection sites within the same body region to reduce the risk of lipodystrophy, which can affect insulin absorption.

Overdose of Ryzodeg Flexpen relative to food intake, energy expenditure, or concurrent glucose-lowering therapy causes hypoglycemia, which may present as sweating, tremor, palpitations, confusion, seizures, or loss of consciousness.

Mild hypoglycemic episodes can usually be managed by immediate intake of oral glucose or sugar-containing food. Severe episodes with loss of consciousness or inability to swallow safely require immediate emergency medical attention — contact emergency services; treatment may include glucagon injection or intravenous glucose administered by trained personnel. Do not attempt to manage a severe overdose at home without professional guidance.

Store unopened pens/vials in a refrigerator (2°C–8°C); do not freeze, and discard if frozen. Once in use, the pen/vial may be kept at room temperature (below 30°C), away from direct heat and light, and must be discarded after the period specified on the product label (commonly around 2–4 weeks), even if it still contains insulin. Keep out of reach of children.

• Renal impairment: insulin requirements may be reduced due to decreased insulin clearance; monitor blood glucose more frequently and adjust dose as needed under medical supervision.
• Hepatic impairment: insulin requirements may be altered due to reduced capacity for gluconeogenesis and insulin metabolism; monitor closely.
• Elderly patients: initiate and titrate conservatively due to increased sensitivity to hypoglycemia and potential for reduced ability to recognize warning symptoms.
• Pediatric patients: approved for use in children 1 year of age and older; not recommended for those requiring less than 5 units per day. Safety and efficacy in children under 1 year of age have not been established.

Ryzodeg Flexpen is generally used as a long-term, ongoing therapy for chronic management of diabetes mellitus, since diabetes requires continuous glycemic control. The duration of treatment is determined by the prescribing physician and is reviewed and adjusted periodically based on blood glucose control, HbA1c results, and overall clinical status. Treatment should not be stopped abruptly without medical advice.

Insulin Degludec + Insulin Aspart Premixed falls under the drug class antidiabetic agents — insulin analogues (premixed ultra-long-acting basal / rapid-acting combination).

Insulin Degludec + Insulin Aspart Premixed works through the combined mechanism of its two components. Insulin aspart binds insulin receptors to rapidly promote peripheral glucose uptake into muscle and fat tissue and suppress hepatic glucose output around mealtimes. Insulin degludec forms a subcutaneous depot of soluble multi-hexamers that slowly dissociate into active monomers, providing a continuous, basal insulin effect that lowers blood glucose steadily over an extended period (see Pharmacology for detail).

Ryzodeg Flexpen is approved for use in pediatric patients 1 year of age and older with diabetes mellitus who require both basal and mealtime insulin coverage. It is not recommended for pediatric patients requiring less than 5 units of total daily insulin dose, due to the difficulty of precise dosing at very low volumes. When switching a child to Ryzodeg Flexpen from another insulin regimen, physicians typically start at a reduced percentage of the prior total daily dose and titrate carefully, with close blood glucose monitoring, because children may be more susceptible to hypoglycemia and may have difficulty recognizing or communicating hypoglycemic symptoms. Safety and efficacy in children under 1 year of age have not been established.